Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Orthopediatrics (KIDS) EBITDA (2016 - 2025)

Orthopediatrics (KIDS) has disclosed EBITDA for 10 consecutive years, with -$8.2 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA rose 41.86% to -$8.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$39.2 million, a 12.08% decrease, with the full-year FY2025 number at -$39.2 million, down 12.08% from a year prior.
  • EBITDA was -$8.2 million for Q4 2025 at Orthopediatrics, up from -$9.4 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$2.8 million in Q2 2021 to a low of -$14.1 million in Q4 2024.
  • A 5-year average of -$7.2 million and a median of -$6.7 million in 2022 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: soared 59.44% in 2021, then crashed 91.03% in 2022.
  • Orthopediatrics' EBITDA stood at -$5.6 million in 2021, then tumbled by 49.42% to -$8.3 million in 2022, then grew by 2.92% to -$8.1 million in 2023, then plummeted by 74.25% to -$14.1 million in 2024, then skyrocketed by 41.86% to -$8.2 million in 2025.
  • Per Business Quant, the three most recent readings for KIDS's EBITDA are -$8.2 million (Q4 2025), -$9.4 million (Q3 2025), and -$10.7 million (Q2 2025).